Clinical Trial Update: Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) [Phase 2]

View source ↗

Summary

Phase 2 study of amatuximab combined with pemetrexed and cisplatin in unresectable malignant pleural mesothelioma was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CISPLATIN (cisplatin)
• Pemetrexed (pemetrexed)
• amatuximab (amatuximab)

Snippet

Sponsor: Morphotek | Conditions: Mesothelioma, Malignant | Phase 2 | Status: TERMINATED | Results posted: 2020-03-17